Analysis of Blood Culture and antibacterial Drugs in Classical empiric therapy vs. D-index-guided early therapy using micafungin for persistent febrile neutropenia.(ABCD-CEDMIC trial)

Analysis of Blood Culture and antibacterial Drugs in Classical empiric therapy vs. D-index-guided early therapy using micafungin for persistent febrile neutropenia.(ABCD-CEDMIC trial) - Analysis of Blood Culture and antibacterial Drugs in RCT to compare empiric antifungal therapy and D-index-guided early therapy (ABCD-CEDMIC trial)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040390

Enrollment

420

Registered

2020-05-13

Start date

2020-04-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological malignancies(acute leukemia, myelodysplastic syndrome, lymphoma, myeloma, and so on)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with hematological malignancies who undergo chemotherapy or stem cell transplantation 2)Aged between 16 and 79 years 3)Expected duration of neutropenia at least 7 days 4)No grade III-IV renal or liver dysfunction 5)ECOG-PS 0-2 6)Written informed consent obtained

Exclusion criteria

Exclusion criteria: 1)Previous history of invasive fungal infection 2)Receiving antifungal agents other than prophylactic administration 3)Suspected active infection 4)Planned to receive antifungal prophylaxis with polyenes or candins 5)Allergic reaction to candins 6)Pregnant or possibly pregnant 7)HIV positive 8)Not suitable for thie trial judged by attending physicians

Design outcomes

Primary

Measure	Time frame
To detect the pathogens and confirm the risk factor	—

Countries

Japan

Contacts

Public ContactAkinao Okamoto

Fujita Health University School of Medicine Hematology

aokamoto@fujita-hu.ac.jp0562939243

Outcome results